Market Overview

UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

Share:
Related BMRN
BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting
Benzinga's M&A Chatter for Monday August 24, 2015
Medivation Destined To Become Biotech Behemoth As Low Risk Pipeline Expands (Seeking Alpha)

Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Hold to Buy and announced a $67.00 price target.

Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701 expansion cohort data remains limited, we believe the pipeline provides multiple additional sources of optionality to drive upside in FY13. We believe the company represents an attractive acquisition candidate near-term while also being one of the few (if any) names that seemingly has a sustainable pathway in place to independently achieve large-cap status longer-term."

BioMarin Pharmaceutical closed at $54.08 on Friday.

Latest Ratings for BMRN

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Aug 2015Deutsche BankMaintainsBuy
Aug 2015Bank of AmericaMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (BMRN)

Get Benzinga's Newsletters